News & Events about Wave Life Sciences Ltd.
CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap Russell 2000 ...
Latest Ratings for WVE
DateFirmActionFromTo Mar 2021SVB LeerinkReiteratesMarket Perform Dec 2020HC Wainwright & Co.AssumesBuy Oct 2020RBC CapitalInitiates Coverage OnSector Perform
View More Analyst Ratings for WVE
View the Latest Analyst Ratings
read more...
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference ...
53% mean exon skipping and PN chemistry improved pharmacology of WVE-N531 compared with Waves first-generation DMD program demonstrated high muscle concentrations with a mean of 42 micrograms/gram WVE-N531 appeared safe and well tolerated Third Wave clinical trial evaluating a PN chemistry-...
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive ...